Historical Valuation
Core Laboratories Inc (CLB) is now in the Fair zone, suggesting that its current forward PE ratio of 22.91 is considered Fairly compared with the five-year average of 26.36. The fair price of Core Laboratories Inc (CLB) is between 16.66 to 30.49 according to relative valuation methord.
Relative Value
Fair Zone
16.66-30.49
Current Price：18.84
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Core Laboratories Inc (CLB) has a current Price-to-Book (P/B) ratio of 2.88. Compared to its 3-year average P/B ratio of 3.75 , the current P/B ratio is approximately -23.32% higher. Relative to its 5-year average P/B ratio of 5.96, the current P/B ratio is about -51.73% higher. Core Laboratories Inc (CLB) has a Forward Free Cash Flow (FCF) yield of approximately 4.36%. Compared to its 3-year average FCF yield of 3.55%, the current FCF yield is approximately 22.72% lower. Relative to its 5-year average FCF yield of 2.73% , the current FCF yield is about 59.84% lower.
P/B
Median3y
3.75
Median5y
5.96
FCF Yield
Median3y
3.55
Median5y
2.73
Competitors Valuation Multiple
AI Analysis for CLB
The average P/S ratio for CLB competitors is 1.70, providing a benchmark for relative valuation. Core Laboratories Inc Corp (CLB.N) exhibits a P/S ratio of 1.52, which is -10.76% above the industry average. Given its robust revenue growth of 0.09%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CLB
1Y
3Y
5Y
Market capitalization of CLB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CLB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CLB currently overvalued or undervalued?
Core Laboratories Inc (CLB) is now in the Fair zone, suggesting that its current forward PE ratio of 22.91 is considered Fairly compared with the five-year average of 26.36. The fair price of Core Laboratories Inc (CLB) is between 16.66 to 30.49 according to relative valuation methord.
What is Core Laboratories Inc (CLB) fair value?
CLB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Core Laboratories Inc (CLB) is between 16.66 to 30.49 according to relative valuation methord.
How does CLB's valuation metrics compare to the industry average?
The average P/S ratio for CLB's competitors is 1.70, providing a benchmark for relative valuation. Core Laboratories Inc Corp (CLB) exhibits a P/S ratio of 1.52, which is -10.76% above the industry average. Given its robust revenue growth of 0.09%, this premium appears unsustainable.
What is the current P/B ratio for Core Laboratories Inc (CLB) as of Jan 09 2026?
As of Jan 09 2026, Core Laboratories Inc (CLB) has a P/B ratio of 2.88. This indicates that the market values CLB at 2.88 times its book value.
What is the current FCF Yield for Core Laboratories Inc (CLB) as of Jan 09 2026?
As of Jan 09 2026, Core Laboratories Inc (CLB) has a FCF Yield of 4.36%. This means that for every dollar of Core Laboratories Inc’s market capitalization, the company generates 4.36 cents in free cash flow.
What is the current Forward P/E ratio for Core Laboratories Inc (CLB) as of Jan 09 2026?
As of Jan 09 2026, Core Laboratories Inc (CLB) has a Forward P/E ratio of 22.91. This means the market is willing to pay $22.91 for every dollar of Core Laboratories Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Core Laboratories Inc (CLB) as of Jan 09 2026?
As of Jan 09 2026, Core Laboratories Inc (CLB) has a Forward P/S ratio of 1.52. This means the market is valuing CLB at $1.52 for every dollar of expected revenue over the next 12 months.